MLAB Mesa Laboratories, Inc.
Mesa Laboratories, Inc. (MLAB) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $800.1K.
Where they traded
Last open-market purchase: August 13, 2026 , by Tripeny R Tony .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Sullivan John James | Director | Sell | 7,093 | $112.80 | $800.1K | 17,834 −28.5% of holding | |
| Kadia Siddhartha | President and CEO | Buy | 7,093 | $112.80 | $800.1K | 7,093 | |
| Tripeny R Tony | Director | Buy | 900 | $113.69 | $102.3K | 6,298 | |
| Sakys John | CFO | Sell | 2,827 | $89.50 | $253.0K | 19,785 −12.5% of holding | |
| Archbold Brian David | SVP Operations | Sell | 2,516 | $89.50 | $225.2K | 6,377 −28.3% of holding | |
| Crennen Lyndsey Elizabeth | CAO | Sell | 442 | $89.50 | $39.6K | 2,020 −18% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.